Lista de obras - Sandra Ribeiro - Dominio Público Uruguay

Adiponectin is an independent predictor of tissue plasminogen activator levels in patients under haemodialysis

artículo científico publicado en 2012

Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients.

artículo científico publicado en 2013

Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses.

artículo científico publicado en 2013

Comparison of Bio-Plex measurements with standard techniques

artículo científico publicado en 2011

Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat.

artículo científico publicado en 2016

Iron as the key modulator of hepcidin expression in erythroid antibody-mediated hypoplasia

artículo científico publicado en 2014

Iron therapy in chronic kidney disease: Recent changes, benefits and risks

artículo científico

Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model

artículo científico publicado en 2015

Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses

artículo científico publicado en 2016

Main Determinants of PON1 Activity in Hemodialysis Patients

artículo científico publicado en 2012

Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients

scientific article published on 27 September 2012

Markers of increased cardiovascular risk in postmenopausal women: focus on oxidized-LDL and HDL subpopulations.

artículo científico publicado en 2013

Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene.

artículo científico publicado en 2012

Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia

artículo científico publicado en 2016

Potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis.

artículo científico publicado en 2014

Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat.

artículo científico publicado en 2016

Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose

artículo científico publicado en 2016

Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia

artículo científico publicado en 2015

Risk factors for mortality in hemodialysis patients: two-year follow-up study.

artículo científico publicado en 2013

Vascular access versus the effect of statins on inflammation and fibrinolysis in renal dialysis patients

artículo científico publicado en 2013

Lista de obras de Sandra Ribeiro

Adiponectin is an independent predictor of tissue plasminogen activator levels in patients under haemodialysis

Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients.

Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses.

Comparison of Bio-Plex measurements with standard techniques

Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat.

Iron as the key modulator of hepcidin expression in erythroid antibody-mediated hypoplasia

Iron therapy in chronic kidney disease: Recent changes, benefits and risks

Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model

Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses

Main Determinants of PON1 Activity in Hemodialysis Patients

Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients

Markers of increased cardiovascular risk in postmenopausal women: focus on oxidized-LDL and HDL subpopulations.

Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene.

Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia

Potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis.

Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat.

Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose

Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia

Risk factors for mortality in hemodialysis patients: two-year follow-up study.

Vascular access versus the effect of statins on inflammation and fibrinolysis in renal dialysis patients

rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits